JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level
Watch the 'KOL Connect' segment here
FRENCHTOWN, NJ / ACCESS Newswire / May 8, 2025 / JTC Team ('JTC'), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor 'KOL Connect' segment featuring Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Key Opining Leader (KOL), Louis J. Aronne, MD, FACP.
Veru Inc. (NASDAQ:VERU) is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.
As part of this 'KOL Connect' segment, Dr. Steiner and Dr. Aronne discussed obesity and GLP-1s, the current treatment landscape and areas of unmet need, highlighting Veru's lead program, the enobosarm QUALITY Phase 2b study, and the clinical data released by Veru to date.
The Virtual Investor 'KOL Connect' segment featuring Veru Inc. is now available here. To access all Virtual Investor Events, visit www.virtualinvestorco.com.
About JTC Team
JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on X and LinkedIn.
CONTACT
Jenene Thomas
JTC Team, LLC
T: +1 (908) 824-0775
[email protected]
SOURCE: JTC Team, LLC
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025
Register for the three-day event here FRENCHTOWN, NJ / / August 15, 2025 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced its companies will present at the Webull Corporate Connect Webinar Series: Biotech/MedTech being held virtually on August 19-21, 2025. The event will feature three days of presentations from participating companies and interactive Q&A sessions. The schedule of presenting companies is: Tuesday, August 19th 2:00 PM ET: Akari Therapeutics, Plc (NASDAQ:AKTX) 2:20 PM ET: Senti Biosciences, Inc. (NASDAQ:SNTI) 2:40 PM ET: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Wednesday, August 20th 2:00 PM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) 2:20 PM ET: GRI Bio, Inc. (NASDAQ:GRI) 2:40 PM ET: AIM ImmunoTech, Inc. (NYSE American:AIM) Thursday, August 21st 2:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) 2:20 PM ET: Autonomix Medical, Inc. (NASDAQ:AMIX) 2:40 PM ET: Nuwellis, Inc. (NASDAQ:NUWE) All investors and interested parties can register for the event and access the schedule of participating companies here. JTC Team is a paid consultant to the participating companies. JTC Team is an investor relations and corporate communications firm. Any content included in this release shall not be construed as an offer to purchase securities of the applicable companies. Interested parties are responsible for conducting their own due diligence and are encouraged to review the companies' websites and the SEC website for the latest information and filings on each company. About JTC Team JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit or connect with the company on X and LinkedIn. Contact: Jenene ThomasJTC Team, LLCT: +1 (908) 824-0775jtc@ SOURCE: JTC Team, LLC View the original press release on ACCESS Newswire
Yahoo
11-08-2025
- Yahoo
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology
NEW YORK, August 11, 2025--(BUSINESS WIRE)--Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced that Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company advancing treatments for cardiometabolic and inflammatory diseases, has selected a novel modified-release oral formulation of enobosarm that will utilize Laxxon's proprietary SPID® (Screen Printing Innovation Drug)-Technology. The novel tablet formulation achieved the desired target release profile, including a reduced maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and a similar extent of absorption (AUC) compared to historical values for immediate release enobosarm capsules. "This milestone underscores the strength of our SPID®-Technology in enhancing bioavailability and optimizing drug release profiles," said Helmut Kerschbaumer, Chief Executive Officer of Laxxon Medical. "The collaboration with Veru reflects our commitment to advancing next-generation drug formulations, and we are excited to support them on their product development pathway." Sequential release of APIs, processing of molecules like peptides in combination with permeation enhancers, processing of nanoparticles, multi-compartment tablets starting at a micro-tablet dimension as small as < 750 micron, are just some of the various possibilities which SPID®-Technology enables, and multiple other functionalities can be combined in one tablet with the potential upscaling from lab to mass production. "Selecting Laxxon as our formulation development partner was a strategic decision, driven by the strength of their SPID® platform and their proven expertise in advanced drug formulation," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. "The resulting modified-release oral formulation of enobosarm has multiple benefits when treating the intended patient population and represents a significant advance over conventional drug product dosage forms as we move towards Phase 3 clinical trials and potential commercialization, pending regulatory approval." About Laxxon MedicalLaxxon Medical Corp. is a leading pharma-technology company and global leader of smart drug delivery systems in the pharmaceutical industry, pioneering a new generation of advanced pharmaceuticals designed to optimize drug delivery and maximize patient success through SPID®-Technology, Laxxon's proprietary screen printing technology platform. SPID®-Technology unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in drug development and commercialization. With SPID®-Technology, Laxxon can develop and manufacture advanced versions of new and existing pharmaceutical drugs while extending and adding new patent protection through the technology transfer process. Laxxon can fully utilize the FDA's 505b(2) regulatory pathway in the US and Hybrid applications under article 10(3) of Directive 2001/83/EC in the EU, which fast tracks product routes to market. Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of >230 patents and patent applications with more than 5,000 patent claims. About Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. For more information, visit View source version on Contacts Laxxon Investor and Media Contacts: IR@ Veru Investor and Media Contact: Samuel FischExecutive Director, Investor Relations and Corporate CommunicationsEmail: veruinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
11-08-2025
- Business Wire
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID ® -Technology
NEW YORK--(BUSINESS WIRE)--Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced that Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company advancing treatments for cardiometabolic and inflammatory diseases, has selected a novel modified-release oral formulation of enobosarm that will utilize Laxxon's proprietary SPID ® (Screen Printing Innovation Drug)-Technology. 'This milestone underscores the strength of our SPID®-Technology in enhancing bioavailability and optimizing drug release profiles,' said Helmut Kerschbaumer, Chief Executive Officer of Laxxon Medical. The novel tablet formulation achieved the desired target release profile, including a reduced maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and a similar extent of absorption (AUC) compared to historical values for immediate release enobosarm capsules. 'This milestone underscores the strength of our SPID ® -Technology in enhancing bioavailability and optimizing drug release profiles,' said Helmut Kerschbaumer, Chief Executive Officer of Laxxon Medical. 'The collaboration with Veru reflects our commitment to advancing next-generation drug formulations, and we are excited to support them on their product development pathway.' Sequential release of APIs, processing of molecules like peptides in combination with permeation enhancers, processing of nanoparticles, multi-compartment tablets starting at a micro-tablet dimension as small as < 750 micron, are just some of the various possibilities which SPID ® -Technology enables, and multiple other functionalities can be combined in one tablet with the potential upscaling from lab to mass production. 'Selecting Laxxon as our formulation development partner was a strategic decision, driven by the strength of their SPID ® platform and their proven expertise in advanced drug formulation,' said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. 'The resulting modified-release oral formulation of enobosarm has multiple benefits when treating the intended patient population and represents a significant advance over conventional drug product dosage forms as we move towards Phase 3 clinical trials and potential commercialization, pending regulatory approval.' About Laxxon Medical Laxxon Medical Corp. is a leading pharma-technology company and global leader of smart drug delivery systems in the pharmaceutical industry, pioneering a new generation of advanced pharmaceuticals designed to optimize drug delivery and maximize patient success through SPID ® -Technology, Laxxon's proprietary screen printing technology platform. SPID ® -Technology unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in drug development and commercialization. With SPID ® -Technology, Laxxon can develop and manufacture advanced versions of new and existing pharmaceutical drugs while extending and adding new patent protection through the technology transfer process. Laxxon can fully utilize the FDA's 505b(2) regulatory pathway in the US and Hybrid applications under article 10(3) of Directive 2001/83/EC in the EU, which fast tracks product routes to market. Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of >230 patents and patent applications with more than 5,000 patent claims. About Veru Inc. Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. For more information, visit
